Prospective Studies on the Immunopathogenesis of Fibrosis in Acute and Chronic Liver Diseases

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The immune system is thought to play a key role in the development of liver inflammation and subsequent liver fibrosis or cirrhosis. In the case of viral hepatitis and autoimmune hepatitis, for example, numerous studies have focused on the acquired antigen-specific immunity. However, the liver is the site of increased occurrence of the components of the innate immune response (NK and NKT cells) and, in contrast to T cells, these T cells, these do not require antigen presentation. Therefore, the present study was designed to determine which cellular components of the (NK, NKT, dendritic cells, macrophages) or the acquired immune response (CD4, CD8) or which network of immune cells is involved in the immunopathogenesis of progressive liver inflammation or the development of liver fibrosis. The aim is to identify lymphocyte populations that exhibit either prognostically favorable or unfavorable characteristics. This should allow conclusions to be drawn for a more targeted and individualized therapy of the respective chronic liver diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with chronic liver disease up to progressive cirrhosis (e.g. ethyltoxic, Viral hepatitis, fatty liver, autoimmune hepatitis, colorectal liver metastases, HCC).

• Patients with elevated liver values undergoing elective abdominal surgery.

• As comparison groups patients with acute hepatitis (e.g. viral or autoimmune genesis) and patients without liver disease.

Locations
Other Locations
Germany
Dept. of Surgery, University Hospital Regensburg
RECRUITING
Regensburg
Contact Information
Primary
Jens M. Werner, MD
jens.werner@ukr.de
+49941944
Backup
Florian Bitterer, MD
florian.bitterer@ukr.de
+49941944
Time Frame
Start Date: 2014-02-01
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 1000
Treatments
Liver disease
Patients with either acute or chronic liver disease
Sponsors
Leads: University of Regensburg

This content was sourced from clinicaltrials.gov